Redox-Active Selenium in Health and Disease: A Conceptual Review

Author(s): Boguslaw Lipinski*.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 19 , Issue 9 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Although it is generally accepted that selenium (Se) is important for life, it is not well known which forms of organic and/or inorganic Se compound are the most biologically active. In nature Se exists mostly in two forms, namely as selenite with fourvalent and selenate with sixvalent cations, from which all other inorganic and organic species are derived. Despite a small difference in their electronic structure, these two inorganic parent compounds differ significantly in their redox properties. Hence, only selenite can act as an oxidant, particularly in the reaction with free and/or protein- bound sulhydryl (SH) groups. For example, selenite was shown to inhibit the hydroxyl radicalinduced reduction and scrambled reoxidation of disulfides in human fibrinogen thus preventing the formation of highly hydrophobic polymer, termed parafibrin. Such a polymer, when deposited within peripheral and/or cerebral circulation, may cause irreversible damage resulting in the development of cardiovascular, neurological and other degenerative diseases. In addition, parafibrin deposited around tumor cells produces a protease-resistant coat protecting them against immune recognition and elimination. On the other hand, parafibrin generated by Ebola’s protein disulfide isomerase can form a hydrophobic ‘spike’ that facilitates virus attachment and entry to the host cell. In view of these specific properties of selenite this compound is a potential candidate as an inexpensive and readily available food supplement in the prevention and/or treatment of cardiovascular, neoplastic, neurological and infectious diseases.

Keywords: Cancer, fibrinogen, hydrophobicity, iron, parafibrin, selenium, viral infections.

Christensen, M.J. Selenium and prostate cancer prevention, What next - if anything? Cancer Prev. Res., 2014, 7(8), 781-785.
Combs, G.F. Jr. Selenium in global food systems. Br. J. Nutr., 2001, 85(8), 517-547.
Duntas, L.H.; Benvenga, S. Selenium, an element for life. Endocrine, 2015, 48(3), 756-775.
Hawkes, W.C.; Alkan, Z. Regulation of redox signaling by selenoproteins. Biol. Trace Elem. Res., 2010, 134, 235-251.
Nuttall, K.L. Evaluating selenium poisoning. Ann. Clin. Lab. Sci., 2006, 36, 409-420.
Chen, J. An original discovery, selenium deficiency and Keshan disease (an endemic heart disease). Asia Pac. J. Clin. Nutr., 2012, 21(3), 320-326.
Rayman, M.P. Food-chain selenium and human health, emphasis on intake. Br. J. Nutr., 2008, 100, 254-268.
Kieliszek, M.; Blazejczak, S. Selenium, Significance and outlook for supplementation. Nutrition, 2013, 29, 713-718.
Papp, L.P.; Holmgren, A.; Khanna, K.K. Selenium and selenoproteins in health and disease. Antioxid. Redox Signal., 2010, 12, 793-795.
Thomson, C.D. Assessment of requirements for selenium and adequacy of selenium status, a review. Eur. J. Clin. Nutr., 2004, 58, 391-402.
Schrauzer, G.N. Selenium and cancer, A review. Bioinorg. Chem., 1976, 5, 275-281.
Rayman, M.P. Selenium and human health. Lancet, 2012, 379, 1256-1268.
Rayman, M.P. Selenium in cancer prevention, a review of the evidence and mechanism of action. Proc. Nutr. Soc., 2005, 64, 527-542.
Lipinski, B. Is it oxidative or free radical stress and why does it matter? Oxid. Antioxid. Med. Sci., 2012, 1, 5-9.
Lipinski, B. Hydroxyl radical and its scavengers in health and disease. Oxid. Cell Med. Longev., 2011.
Behne, S.S.; Kyriakopoulos, A. Mammalian selenium-containing proteins. Annu. Rev. Nutr., 2001, 21, 453-473.
Li, F.; Lutz, P.B.; Pepelyaeva, Y.; Arner, E.S.J.; Bayse, C.A.; Rozovsky, S. Redox active motifs in selenoproteins. Proc. Natl. Acad. Sci. USA, 2014, 111, 6976-6981.
Ip, C. Lessons from basic research in selenium and cancer prevention. J. Nutr., 1998, 128, 1845-1854.
Vinceti, M.; Maraldi, T.; Bergomi, M.; Malagoli, C. Risk of chronic-low dose selenium overexposure in humans, Insights from epidemiology and biochemistry. Rev. Environ. Health, 2009, 24, 231-248.
Whanger, P.D. Selenium and its relationship to cancer, an update. Br. J. Nutr., 2004, 91, 11-28.
Spallholz, J.E. Free radical generation by selenium compounds and their prooxidant toxicity. Biomed. Environ. Sci., 1997, 10, 260-270.
Wang, Z.; Vincent, J.L.; Forceville, X. A large-bolus injection, but not continuous infusion of sodium selenite improves outcome in peritonitis. Shock, 2010, 33, 555.
Lipinski, B.; Pretorius, E. Novel pathway of iron-induced blood coagulation, Implications for diabetes mellitus and its complications. Pol. Arch. Med. Wewn., 2012, 122, 116-122.
Lipinski, B. Hydroxyl radical and its scavengers in health and disease. Oxid. Med. Cell. Longev., 2011, DOI, 10.1155/2011/8099696.
Lipinski, B.; Pretorius, E. The role of iron-induced fibrin in the pathogenesis of Alzheimer’s disease and the protective role of magnesium. Front. Hum. Neurosci., 2013, 7, 735.
Lipinski, B. Iron-induced parafibrin formation in tumors fosters immune evasion. OncoImmunology, 2014, 3, e28539, 2014.
Weekley, C.M.; Harris, H.H. Which form is that? The importance of selenium speciation in the prevention and treatment of disease. Chem. Soc. Rev., 2013, 42, 8870-8894.
Combs, G.F., Jr Status of selenium in prostate cancer prevention. Br. J. Cancer, 2004, 91(2), 195-199.
Davis, C.D.; Tsuji, P.A.; Milner, J.A. Selenoproteins and cancer prevention. Annu. Rev. Nutr., 2012, 32, 73-95.
Fernandes, A.P.; Gandin, V. Selenium compounds as therapeutic agents in cancer. Biochim. Biophys. Acta, 2014.
[ j.bbagen.2014.10.008]
Jackson, M.I.; Combs, G.F., Jr Selenium and anticarcinogenesis, Underlying mechanisms. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11(6), 718-726.
Sanmartin, C.; Plano, D.; Font, M.; Palop, J.A. Selenium and clinical trials, new therapeutic evidence for multiple diseases. Curr. Med. Chem., 2011, 18, 4635-4650.
Sinha, R.; Medina, S.D. Organic and inorganic selenium compounds inhibit mouse mammary cell growth in vitro by different cellular pathways. Cancer Lett., 1996, 107, 277-284.
Bao, P.; Chen, Z.; Tai, R.; Shen, H.; Martin, F.L.; Zhu, Y. Selenite-induced toxicity in cancer cells is mediated by metabolic generation of endogenous selenium nanoparticles. J. Proteome Res., 2015, 14(2), 1127-1136.
Caffrey, P.B.; Frenkel, G.D. Inhibition of cell colony formation by selenite, involvement of glutathione. Mol. Pharmacol., 1991, 39(3), 281-284.
Chen, J.; Berry, M.J. Selenium and selenoproteins in the brain and brain diseases. J. Neurochem., 2003, 86, 1-12.
Frenkel, G.D.; Falvey, D.; MacVicar, C. Products of the reaction of selenite with intracellular sulfhydryl groups. Biol. Trace Elem. Res., 1991, 30, 9-18.
Lothrop, A.P.; Snider, G.W.; Ruggles, E.L.; Patel, A.S.; Lees, W.J.; Hondal, R.J. Selenium as an electron acceptor during the catalytic mechanism of thioredoxin reductase. Biochemistry, 2014, 53, 654-663.
Husbeck, B.; Peehl, D.M.; Knox, S.J. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic. Biol. Med., 2005, 38, 50-57.
Park, S.H.; Kim, J.H.; Chi, G.Y.; Kim, G.Y.; Chang, Y.C.; Moon, S.K.; Nam, S.W.; Kim, W.J.; Yoo, Y.H.; Choi, Y.H. Induction of apoptosis and autophagy by sodium selenite in A549 human lung.
Kralova, V.; Brigulova, K.; Cervinka, M.; Rudolf, E. Antiproliferative and cytotoxic effects of sodium selenite in human colon cancer. Toxicol. In Vitro, 2009, 23, 1497-1503.
Kuklinski, B.; Zimmermann, T.; Schweder, R. Decreasing mortality in acute pancreatitis with sodium selenite. Clinical results of 4-year antioxidant therapy. Med. Klin. (Munich), 1995, 90, 36-41.
de Miranda, J.X.; Andrade, F.O.; de Conti, A.; Daghli, M.L.Z.; Moreno, F.S.; Ong, T.P. Effects of selenium compounds on proliferation and epigenetic marks of breast cancer cells. J. Trace Elem. Med. Biol., 2014, 28(4), 486-491.
Xu, W.; Ma, W-W.; Zeng, H-H. Synergetic effect of ethaselen and selenite treatment against A549 non-small cell lung cancer cells. Asian Pac. J. Cancer Prev., 2014, 15, 7129-7135.
Yang, Y.; Huang, F.; Ren, Y.; Xing, L.; Wu, Y.; Li, Z.; Pan, H.; Xu, C. The anticancer effects of sodium selenite and selenomethionine on human colorectal carcinoma cell lines in nude mice. Oncol. Res., 2009, 18(1), 1-8.
Nelson, M.A.; Porterfield, B.W.; Jacobs, E.T.; Clark, L.C. Selenium and prostate cancer prevention. Semin. Urol. Oncol., 1999, 17, 91-96.
Platz, E.A.; Helzlsouer, K.J. Selenium, zinc, and prostate cancer. Epidemiol. Rev., 2001, 23, 93-101.
Kenfield, S.A.; Van Blarigan, E.L.; DuPre, N.; Stampfer, M.J.; Giovannucci, E.; Chan, J.M. Selenium supplementation and prostate cancer mortality. J. Natl. Cancer Inst, 2014, 107, (1), pii, dju360.
Lipinski, B. Rationale for the treatment of cancer with sodium selenite. Med. Hypotheses, 2005, 64, 806-810.
Lipinski, B. Prostate cancer vaccines, fibrin and selenium, A conceptual review. Open Prostate Cancer J., 2010, 3, 69-73.
Zhao, R.; Xiang, N.; Domann, F.E.; Zhong, W. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr. Cancer, 2009, 61, 397-407.
Freitas, M.; Alves, V.; Sarmento-Ribeiro, A.B.; Mota-Pinto, A. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line. Biochem. Biophys. Res. Commun., 2011, 408(4), 713-719.
Cekan, E.; Tribukait, B.; Vocal-Borek, H. Protective effect of selenium against ionizing radiation-induced malformation in mice. Acta Radiol., 1985, 24, 267-271.
Ghandi, U.H.; Kaushal, N.; Hegde, S.; Finch, E.R.; Kudva, A.K.; Kennett, M.J.; Jordan, C.T.; Paulson, R.F.; Prabhu, K.S. Selenium suppresses leukemia through the action of endogenous eicosanoids. Cancer Res., 2014, 74(14), 3890-3901.
Wu, S.; Bao, Y.; Ma, D.; Zi, Y.; Yang, C.; Yang, M.; Xing, M.; Yang, W. Sodium selenite inhibits leukemia HL-60 cell proliferation and induces cell apoptosis by enhancing the phosphorylation of JNK1 and increasing the expression of p21 and p27. Int. J. Mol. Med., 2014, 34(4), 1175-1179.
Yang, Y.; Pan, H.; Xu, C. Requirement for ERK activity in sodium selenite-induced apoptosis of acute promyelocytic leukemia-derived NB4 cells. J. Biochem. Mol. Biol., 2007, 40(2), 196-204.
Olm, E.; Johnsson-Videsater, K.; Ribera-Cortada, I.; Fernandes, A.P.; Eriksson, L.C.; Lehmann, S.; Rundlof, A.K.; Paul, C.; Bjornstedt, M. Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett., 2009, 282, 116-123.
Pan, H.Z.; Zhang, Z.N. Distinct effects of different concentrations of sodium selenite on apoptosis, cell cycle, and gene expression profile in acute promyeolytic leukemia-derived NB4 cells. Ann. Hematol., 2006, 85, 434-442.
Jiang, X.R.; Macey, M.G.; Lin, H.X.; Newland, A.C. The anti-leukemic effect and mechanism of sodium selenite. Leuk. Res., 1992, 16, 347-352.
Zuo, L.; Li, J.; Yang, Y.; Wang, X.; Shen, T.; Xu, C.M.; Zhang, Z.N. Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide. Ann. Hematol., 2004, 83(12), 751-758.
Arthur, J.R.; McKenzie, R.C.; Beckett, G.J. Selenium in the immune system. J. Nutr., 2003, 133(5)(Suppl. 1), 1457S-1459S.
McKenzie, R.C.; Rafferty, T.S.; Beckett, G.J. Selenium, an essential element for immune function. Immunol. Today, 1998, 19, 342-345.
Turner, R.J.; Finch, J.M. Selenium and the immune response. Proc. Nutr. Soc., 1991, 50, 275-285.
Taylor, E.W. Selenium and cellular immunity. Biol. Trace Elem. Res., 1995, 49, 85-95.
Taylor, E.W.; Cox, A.G.; Zhao, L.; Ruzicka, J.A.; Bhat, A.A.; Zhang, W.; Nadimpalli, R.G.; Dean, R.G. Nutrition, HIV, and drug abuse, The molecular basis of a unique role for selenium. JAIDS., 2000, 25, S53-S61.
Dhur, A.; Galan, P.; Hercberg, S. Relationship between selenium, immunity and resistance against infection. Comp. Biochem. Physiol., 1990, 96C, 271-280.
Davis, C.D.; Brooks, L.; Calisi, C.; Bennett, B.J.; McElroy, D.M. Beneficial effect of selenium supplementation during murine infection with Trypanosoma cruzi J. Parazitol., 1998, 84, 1274-1277.
Taguchi, N.; Hatabu, T.; Yamaguchi, H.; Suzuki, M.; Sato, K.; Kano, S. Plasmodium falciparum, selenium-induced cytotoxicity to P. falciparum. Exp. Parasitol., 2004, 106, 50-55.
Alhazzani, W.; Jacobi, J.; Sindi, A.; Hartog, C.; Reinhart, K.; Kokkoris, S.; Gerlach, H.; Andrews, P.; Drabek, T.; Manzanares, W.; Cook, D.J.; Jaeschke, R.Z. The effect of selenium therapy on mortality in patients with sepsis syndrome, a systematic review and meta-analysis of randomized controlled trials. Crit. Care Med., 2013, 41, 1555-1564.
Forceville, X. The effect of selenium therapy on mortality in patients with sepsis syndrome, simple selenium supplementation or real (5H2O)·Na2SeO3 pharmacological effect? Crit. Care Med., 2013, 41, 1591-1592.
Huang, T-S.; Shyu, Y-C.; Chen, H-Y.; Lin, L-M.; Lo, C-Y.; Yuan, S-S.; Chen, P-J. Effect of parenteral selenium supplementation in critically ill patients, a systematic review and meta-analysis. PLoS One, 2013, 8, e54431.
Manzanares, W.; Langlois, P.L.; Heyland, D.K. Pharmaconutrition with selenium in critically ill patients, what do we know? Nutr. Clin. Pract., 2015, 30(1), 34-43.
Sakr, Y.; Maia, V.P.; Santos, C.; Stracke, J.; Zeidan, M.; Bayer, O.; Reinhart, K. Adjuvant selenium supplementation in the form of sodium selenite in postoperative critically ill patients with severe sepsis. Crit. Care, 2014, 18, R68.
Beck, M.A.; Nelson, H.K.; Shi, Q.; van Dael, P.; Schiffrin, E.J.; Blum, S.; Barclay, D.; Levander, O.A. Selenium deficiency increases the pathology of an influenza virus infection. FASEB J., 2001, 15(8), 1481-1483.
Sighal, N.; Austin, J. A clinical review of micronutrients in HIV infection. J. Int. Assoc. Physic. AIDS Care, 2002, 1, 63-75.
van Zuuren, E.J.; Albusta, A.Y.; Fedorowicz, Z.; Carter, B.; Pijl, H. Selenium supplementation for Hashimoto’s thyroiditis. Cochrane Database Syst. Rev., 2013, 6, CDO10223.
Landuci, F.; Mancinelli, P.; De Gaudio, A.R.; Virgili, G. Selenium supplementation in critically ill patients, a systematic review and meta-analysis. J. Crit. Care, 2014, 29(1), 150-156.
Conner, T.S.; Richardson, A.C.; Miller, J.C. Optimal serum selenium concentrations are associated with lower depressive symptoms and negative mood among young adults. J. Nutr, 2014, pii, jn.114.198010.
Ramaekers, V.T.; Calomme, M.; Vanden Berghe, D.; Makropoulos, W. Selenium deficiency triggering intractable seizures. Neuropediatrics, 1994, 25, 217-223.
Sakr, Y.; Maia, V.P.; Santos, C.; Stracke, J.; Zeidan, M.; Bayer, O.; Reinhart, K. Adjuvant selenium supplementation in the form of sodium selenite in postoperative critically ill patients with severe sepsis. Crit. Care, 2014, 18, R68.
Imam, S.Z.; Newport, G.D.; Islam, F.; Slikker, W.; Ali, S.F. Selenium, an antioxidant, protects against methamphetamine-induced dopaminergetic neurotoxicity. Brain Res., 1999, 818, 575-578.
Stranges, S.; Sieri, S.; Vinceti, M.; Grioni, S.; Guallar, E.; Laclaustra, M.; Muti, P.; Berrino, F.; Krogh, V. A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health, 2010, 10, 564.
Zhou, J.; Huang, K.; Lei, X.G. Selenium and diabetes-evidence from animal studies. Free Radic. Biol. Med., 2013, 65, 1548-1556.
Allam, M.F.; Lucane, R.A. Selenium supplementation for asthma. Cochrane Database Syst. Rev., 2004, 2, CD003538.
Gazdik, F.; Pijak, M.R.; Gazdikova, K. Need of complementary therapy with selenium in asthmatics. Nutrition, 2004, 20, 950-952.
Misso, N.L.; Powers, K.A.; Gillon, R.L.; Stewart, G.A.; Thompson, P.J. Reduced platelet glutathione peroxidase activity and serum selenium concentration in atopic asthmatic patients. Clin. Exp. Allergy, 1996, 26, 838-847.
Stone, J.; Hinks, L.J.; Beasley, R.; Holgate, S.T.; Clayton, B.A. Reduced selenium status of patients with asthma. Clin. Sci., 1989, 77, 495-500.
Hasselmark, L.; Malmgren, R.; Zetterstrom, O.; Unge, G. Selenium supplementation in intrinsic asthma. Allergy, 1993, 48, 30-36.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [720 - 726]
Pages: 7
DOI: 10.2174/1389557517666161104125022
Price: $58

Article Metrics

PDF: 19